Allarity Therapeutics, Inc. (ALLR)
After hours:
| Previous Close | 1.5000 |
| Open | 1.5000 |
| Bid | 1.1000 x 200 |
| Ask | 1.5500 x 100 |
| Day's Range | 1.2800 - 1.5400 |
| 52 Week Range | 1.2800 - 535.2000 |
| Volume | |
| Avg. Volume | 468,282 |
| Market Cap | 2.997M |
| Beta (5Y Monthly) | 0.24 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -205.2000 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
GlobeNewswireAllarity Therapeutics Receives NASDAQ-Approved Extension to Regain Compliance with Nasdaq Listing Rule 5550(b)(1)
Boston (April 17, 2024)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced that it had been granted an extension until May 14, 2024, to regain compliance with Nasdaq Listing Rule 5550(b)(1). On February 1, 2024, Allarity Therapeutics presented a strategic plan to the Nasdaq Hearings Panel, detailing both immediate and long-term strategies aimed at regaining compl
- GlobeNewswire
Allarity Therapeutics Announces 1-for-20 Reverse Stock Split
Boston (April 4, 2024) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced the implementation of a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-20 (the “Reverse Stock Split”). The Reverse Stock Split will become effective at 9:30 a.m. Eastern Time on April 9, 2024. The Company’s common stock will begin trading on a split-adju
- GlobeNewswire
Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian Cancer
The stenoparib Phase 2 monotherapy trial in advanced, recurrent ovarian cancer continues to show promise, prompting shift in resources to accelerate stenoparib development Further development of IXEMPRA® and dovitinib is de-prioritizedThe Company has been able to reduce costs materially Boston (March 27, 2024) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced
